Lilly to Announce 2019 Financial Guidance, Highlight Late-Stage Pipeline Opportunities and Discuss Commercial Performance at Upcoming Investment Community Meeting


INDIANAPOLIS, Nov. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that it will host a meeting for the investment community on Wednesday, December 19, 2018, from 9:00 a.m. (EST) until approximately 12:00 p.m.

Earlier that day, the company will announce its financial guidance for 2019. At the investment community meeting, Lilly leadership will further detail the 2019 financial guidance and discuss progress towards the company's strategic goals, as well as the commercial performance of recently launched medicines. A substantial portion of the meeting will then focus on Lilly's research and development opportunities in the areas of oncology, pain, neurodegeneration, immunology and diabetes.

Meeting attendees will include institutional investors, sell-side analysts, ratings agency representatives, and financial and business media. Because of limited space, advance registration is required and in-person attendance is by invitation only. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at A replay of the presentation will be available on this same website for approximately 90 days.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at and  F-LLY   

Refer to:

Mark Taylor;; (317) 276-5795 (Media)

Kevin Hern;; (317) 277-1838 (Investors)


Eli Lilly and Company logo. (PRNewsfoto/Eli Lilly and Company)


Cision View original content to download multimedia:

SOURCE Eli Lilly and Company